Skip to main content
Journal cover image

Temozolomide in children with progressive low-grade glioma.

Publication ,  Journal Article
Gururangan, S; Fisher, MJ; Allen, JC; Herndon, JE; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Desjardins, A; Phillips, PC; Watral, MA ...
Published in: Neuro Oncol
April 2007

We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4-18 years). Eligible patients received TMZ (200 mg/m(2) per day) by mouth for five days every four weeks. Patients received a median of nine cycles (range, 2-12 cycles) of treatment. Best responses in the 26 patients (86%) with optic pathway glioma (OPG)/pilocytic astrocytoma (PA) included partial response in 3 patients (11%), minor response in 1 (4%), stable disease in 10 (38%), and progressive disease in 12 (46%). Only one of four patients with fibrillary astrocytoma had stable disease for 29 months after TMZ. The overall disease stabilization rate in patients with OPG/PA was 54%, and disease control was maintained for a median interval of 34 months. Seventeen of 26 patients had progressive disease either on or off therapy, and three have died of disease. The two-year progression-free and overall survivals in patients with OPG/PA were 49% (95% CI, 30%-67%) and 96% (95% CI, 89%-100%), respectively. Worst toxicity related to TMZ in all 30 patients included grade 2-4 thrombocytopenia in seven patients, grade 2-4 neutropenia in seven, grade 2 skin rash in one, and intratumor hemorrhage in one. TMZ given in this schedule was successful in stabilizing disease in a significant proportion of the patients with OPG/PA, with manageable toxicity.

Duke Scholars

Published In

Neuro Oncol

DOI

ISSN

1522-8517

Publication Date

April 2007

Volume

9

Issue

2

Start / End Page

161 / 168

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Temozolomide
  • Survivors
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Glioma
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gururangan, S., Fisher, M. J., Allen, J. C., Herndon, J. E., Quinn, J. A., Reardon, D. A., … Friedman, H. S. (2007). Temozolomide in children with progressive low-grade glioma. Neuro Oncol, 9(2), 161–168. https://doi.org/10.1215/15228517-2006-030
Gururangan, Sridharan, Michael J. Fisher, Jeffrey C. Allen, James E. Herndon, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, et al. “Temozolomide in children with progressive low-grade glioma.Neuro Oncol 9, no. 2 (April 2007): 161–68. https://doi.org/10.1215/15228517-2006-030.
Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007 Apr;9(2):161–8.
Gururangan, Sridharan, et al. “Temozolomide in children with progressive low-grade glioma.Neuro Oncol, vol. 9, no. 2, Apr. 2007, pp. 161–68. Pubmed, doi:10.1215/15228517-2006-030.
Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007 Apr;9(2):161–168.
Journal cover image

Published In

Neuro Oncol

DOI

ISSN

1522-8517

Publication Date

April 2007

Volume

9

Issue

2

Start / End Page

161 / 168

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Temozolomide
  • Survivors
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Glioma
  • Female